Business Wire

Brand Finance Global 500 2025: Apple Is the Most Valuable Brand in the World, NVIDIA Enters Top Ten

21.1.2025 17:22:00 EET | Business Wire | Press release

Share

Apple is once again the world’s most valuable brand. Brand Finance, the world’s leading brand valuation consultancy, values Apple’s brand at USD574.5 billion, ahead of second-placed Microsoft (USD461 billion).

According to Brand Finance’s research, four out of the five most valuable brands in the world are technology brands:

  1. Apple: brand value of USD574.5 billion, up 11% from 2024
  2. Microsoft: USD461.1 billion, up 35%
  3. Google: USD413.0 billion, up 24%
  4. Amazon: USD356.4 billion, up 15%
  5. Walmart: USD137.2 billion, up 42%

Brand Finance also analysed what brands have grown the most since 2020, plus TikTok – although Brand Finance began valuing the brand in 2022, its 79% growth in four years puts it in the same league as the other high-growth brands.

  1. TikTok/Douyin: USD105.8 billion, up from USD59.0 billion (in 2022)
  2. DraftKings: USD5.1 billion, up from USD18 million
  3. FanDuel: USD7.0 billion, up from USD56 million
  4. NVIDIA: USD87.9 billion, up from USD4.7 billion
  5. AMD: USD11.0 billion, up from USD1.4 billion
  6. Pinduoduo: USD13.0 billion, up from USD2.5 billion
  7. BYD: USD14.0 billion, up from USD3.1 billion
  8. Apple: USD574.5 billion, up from USD140.5 billion
  9. TSMC: USD34.2 billion, up from US8.6 billion
  10. Microsoft: USD461.1 billion, up from USD117.1 billion
  11. Lilly: USD8.0 billion, up from USD2.1 billion

American gambling brands DraftKings and FanDuel are cashing in as online gambling becomes legal in more American states. Semiconductor brands NVIDIA, AMD, and TSMC advance new technologies, while tech giants Apple and Microsoft lead from the front.

David Haigh, Founder & CEO, Brand Finance, commented:

“Our analysis of what brands have grown the most since 2020 reveals that technology companies do not have a monopoly on sustained brand growth. This also reinforces another global trend: how Chinese brands like TikTok, Pinduoduo, and BYD lead the charge by creating value and challenging established brand leaders.”

e& is the world’s fastest growing brand value, posting an eight-fold increase following consolidation of brand architecture.

WeChat is the strongest brand, with a Brand Strength Index score of 95.2/100.

View the full Brand Finance Global 500 2025 report here

See details of Brand Finance’s methodology here, along with frequently asked questions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121799865/en/

Contacts

Jamie Hyman
press@brandfinance.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye